APLLTD vs COHANCE: Stock Comparison
Cohance Lifesciences Limited is the larger company by market capitalisation. Alembic Pharmaceuticals Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Cohance Lifesciences Limited shows lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APLLTD leads 11; COHANCE leads 2 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | APLLTD | COHANCE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | APLLTD | COHANCE |
|---|---|---|
| Live Price | ₹821.75 | ₹463 |
| Day Change | 0.94% | -2.64% |
| Volume | 35,565 | 16.39 L |
| 52-Week High | ₹998 | ₹1,038.9 |
| 52-Week Low | ₹635.8 | ₹266.7 |
| Distance from 52W High | -17.66% | -55.43% |
Valuation
| Metric | APLLTD | COHANCE |
|---|---|---|
| Market Cap | ₹16,15,257.47 L Cr | ₹17,71,425.64 L Cr |
| P/E Ratio | 23.3x | 167.27x |
| P/B Ratio | 2.85x | 4.55x |
| EPS | ₹35.25 | ₹2.78 |
| Book Value | ₹288.7 | ₹102.03 |
| Dividend Yield | 1.46% | 0% |
Growth
| Metric | APLLTD | COHANCE |
|---|---|---|
| Revenue Growth (TTM YoY) | 4.4% | -26.3% |
| EPS Growth (TTM YoY) | 29.2% | -89% |
| Qtr Sales Growth | 4.41% | -26.3% |
| Qtr Profit Growth | 40.8% | -86.6% |
Profitability & Leverage
| Metric | APLLTD | COHANCE |
|---|---|---|
| ROE | 13.4% | 7.04% |
| ROCE | 12.6% | 8.35% |
| Net Margin | 8.98% | 7.9% |
| Operating Margin | 15.2% | 18.8% |
| Debt to Equity | 0.25x | 0.1x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | APLLTD | COHANCE |
|---|---|---|
| Promoter Holding | 69.36%▲ 0.13 pp | 0% |
| FII Holding | 4.18%▼ 0.07 pp | 6.5%▲ 0.91 pp |
| DII Holding | 15.94%▼ 0.24 pp | 20.09%▼ 1.7 pp |
| Public Holding | 10.01%▲ 0.18 pp | 15.92%▲ 0.8 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Alembic Pharmaceuticals Limited and Cohance Lifesciences Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.